Definiens introduced a suite of services to help companies gather data from tissue samples and use the resource to identify potential companion diagnostics. The company, which was acquired by AstraZeneca's ($AZN) MedImmune late last year, views the service as a way for oncology drug developers to pick the strongest biomarker signals to advance into clinical development. Release